AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries
Executive Summary
The drug purchasing group UNITAID may succeed in getting pharmaceutical companies to pool patents on their AIDS medicines. So far, it has won buy-in of the idea from three: Gilead Sciences, Merck and Johnson & Johnson subsidiary Tibotec
You may also be interested in...
Gilead Is First Splash In HIV Patent Pool; Five Other Firms In Negotiations
Gilead's deal with the Medicines Patent Pool limits the developing countries that have access to generics and requires that the drugs be manufactured in India.
WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines
How can governments and industry boost research and development on diseases prevalent in developing countries
WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines
How can governments and industry boost research and development on diseases prevalent in developing countries